Smith Weber Lara, serving as Chief Financial Officer for FRACTYL HEALTH, INC. (NASDAQ:GUTS), executed a recent acquisition of company shares through open market channels. The transaction, finalized on June 8, 2026, involved the purchase of 20,000 shares of common stock valued at $13,708. The weighted average acquisition price stood at $0.6854 per share, with the execution falling within a narrow band of $0.6844 to $0.6896. Post-transaction, Ms. Lara holds a direct stake of 20,000 Fractyl Health common shares.
This insider activity unfolds against a backdrop of depressed equity valuation. The stock was trading at $0.66, hovering close to its 52-week low of $0.38, following a 16% decline over the preceding week. According to InvestingPro analysis, which outlines 13 additional ProTips for GUTS, the equity appears overvalued relative to its Fair Value estimate. Fractyl Health maintains a weak financial health score, although liquid assets remain sufficient to cover short-term obligations.
Financial performance data from the first quarter of 2026 indicates a divergence from consensus forecasts. The company reported an earnings per share of -$0.06, significantly outperforming the analyst expectation of -$0.25. This result was achieved despite the generation of zero revenue. Analysts attributed the positive variance to strategic cost management initiatives and progress in clinical trial operations.
Clinical developments were highlighted through the announcement of REVEAL-1 study results. The data demonstrated that participants retained approximately 78% of the weight lost through GLP-1 medications one year after discontinuing the drugs and undergoing a single Revita procedure. The study cohort consisted of 22 individuals with obesity who had previously achieved an average reduction of 24% of total body weight while on GLP-1 therapy.
Leadership changes were also disclosed with the appointment of Mike Zumdahl as Senior Vice President of Market Access and Commercial Strategy. Zumdahl joins Fractyl Health following his tenure at Inari Medical, where he contributed to the company's expansion prior to its acquisition by Stryker. His background in market access and commercial strategy is intended to support the company's future operational objectives. These developments underscore Fractyl Health's focus on strategic positioning and commercial execution within the specialty healthcare sector.